{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/gout/prescribing-information/allopurinol/","result":{"pageContext":{"chapter":{"id":"2d2fee49-9ad0-5f0a-9ef1-f253794ed2c7","slug":"allopurinol","fullItemName":"Allopurinol","depth":2,"htmlHeader":"<!-- begin field eeebe32a-9b5c-4fbd-b19f-2961c9dcad6a --><h2>Allopurinol</h2><!-- end field eeebe32a-9b5c-4fbd-b19f-2961c9dcad6a -->","summary":"","htmlStringContent":"<!-- begin item aaf3d7ee-8202-4280-93c9-c1e2a6f1f4e7 --><!-- end item aaf3d7ee-8202-4280-93c9-c1e2a6f1f4e7 -->","topic":{"id":"7ec7842e-cb8a-5712-bb55-65480a391cb5","topicId":"b578fac4-ab4b-4d7b-9df9-2136b4d90e75","topicName":"Gout","slug":"gout","lastRevised":"Last revised in February 2018","chapters":[{"id":"2e71494e-f9a3-5368-8903-3d2121329748","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"738bb44e-1a50-5bc5-8df4-83ac66475493","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"69338c48-0d43-5ae0-9591-5ef289880366","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"0f7680ff-9a88-520a-b2b5-1ff130dfa69b","slug":"changes","fullItemName":"Changes"},{"id":"ae66c6f1-78f9-5532-b310-9d6957882c0c","slug":"update","fullItemName":"Update"}]},{"id":"5de6e4cf-e0c8-56e2-a357-3d063b324cd0","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"86664a1d-e3e5-58c9-957b-56affa17f103","slug":"goals","fullItemName":"Goals"},{"id":"39593d8e-f904-5b99-80e9-e619caf1ec37","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"ca59f248-a0b2-5f6c-bfcf-2333dc94f1d9","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"57ca55f4-826e-5832-85a7-dd89f3486be2","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"621c09b7-b5e8-593b-aeb2-fc4a86b884c8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b39fbed2-7c0d-5440-a769-bab311a7b4d2","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"362edeaf-2f90-506d-b203-f5dbbbfb5835","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"a8de4056-6ec0-59ff-911b-561bf7fdb32d","slug":"definition","fullItemName":"Definition"},{"id":"45a8241d-2a2d-5a48-a6d6-2b5ebe02ec27","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"92d229bf-8656-5cfa-aecc-9c069389300f","slug":"prevalence","fullItemName":"Prevalence"},{"id":"79d3b1c2-8d49-55be-99af-41b37c84d582","slug":"complications","fullItemName":"Complications"},{"id":"27dd91cd-92bb-5c2d-8fe8-a184bffce6e7","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"ca0e383b-327b-58c2-adb4-6c5081b6fd8e","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ddea0193-0c14-53db-8e1e-2e71f514988e","slug":"assessment","fullItemName":"Assessment"},{"id":"5a86623b-b32c-5e12-b9fe-b1b5a1f7e58f","slug":"investigations","fullItemName":"Investigations"},{"id":"42a5d4a2-b908-5027-8fb8-f5f336db4c7e","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5a915955-8e0e-54ae-a1cc-f5875d84d2a2","fullItemName":"Management","slug":"management","subChapters":[{"id":"8a8b4d2a-4efb-5bef-9780-70dc540d41bd","slug":"acute-gout","fullItemName":"Scenario: Acute gout"},{"id":"98793041-11dd-5159-a376-82f5440ee713","slug":"preventing-gout","fullItemName":"Scenario: Preventing gout"}]},{"id":"050e571e-a7a5-5659-9790-2daf0b56580a","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"e7cfef3f-4ab1-5d17-8300-30e91a70eb96","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"cadf7df3-5301-560b-a8ff-e85cfee9ba7c","slug":"colchicine","fullItemName":"Colchicine"},{"id":"60f4beab-f8fc-50e5-8ed9-5073dd8533ec","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"2d2fee49-9ad0-5f0a-9ef1-f253794ed2c7","slug":"allopurinol","fullItemName":"Allopurinol"},{"id":"9830ccbd-f551-5585-a69a-4674759f70cd","slug":"febuxostat","fullItemName":"Febuxostat"},{"id":"ff3edf82-1b21-591c-a8a5-a3b40e7386a5","slug":"paracetamol","fullItemName":"Paracetamol"}]},{"id":"776d98f0-f8da-57c2-983e-1291ac67b761","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[{"id":"71a86333-9110-5847-a2c2-eabf7903c269","slug":"application-of-an-ice-pack","fullItemName":"Application of an ice pack"},{"id":"25688946-80c0-52ab-a32d-99ccab4d738c","slug":"nsaids","fullItemName":"NSAIDs"},{"id":"2921e0f0-467f-5231-87d0-9fed766653ee","slug":"oral-colchicine","fullItemName":"Oral colchicine"},{"id":"09bbf9d4-fe62-5ae1-bc49-f2fede12f711","slug":"corticosteroids","fullItemName":"Corticosteroids"},{"id":"409d2bc0-16d2-5104-8857-eeb5db2a1ecc","slug":"dietary-measures","fullItemName":"Dietary measures"},{"id":"08526f72-ca5a-50db-94b6-3380365360fd","slug":"colchicine-to-prevent-recurrent-gout","fullItemName":"Colchicine to prevent recurrent gout"},{"id":"a53517a7-6d7e-5d2f-886d-e2a3f1bc27b1","slug":"urate-lowering-drugs-in-prevention","fullItemName":"Urate-lowering drugs in prevention"}]},{"id":"f83d98a9-6ce1-50d4-92ad-dd354662a444","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"568c43a6-b0d8-546e-84d2-45781ce305cc","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"5b7cac11-c21d-59fc-83d9-bf16d0d3ab0b","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"0e4d0013-b7bc-5179-ac55-8104dec2762c","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"d75afbe0-7c3d-504e-b369-e56eac297bad","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"45249d1d-8c92-5402-b4f3-108a8a39d94f","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"44f1a411-2cf4-55e8-b5e8-266cd568655e","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"050e571e-a7a5-5659-9790-2daf0b56580a","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"5fcec1f5-e09b-5024-94e2-3733f8b8e874","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field bd165f98-2562-408b-a5f0-f999637ddf82 --><h3>How should I prescribe allopurinol?</h3><!-- end field bd165f98-2562-408b-a5f0-f999637ddf82 -->","summary":"","htmlStringContent":"<!-- begin item 71b1f4b2-30fa-4773-90d1-a8dbf2e752a2 --><!-- begin field e7ec73e6-3ab2-4503-a0e8-283e555a1802 --><ul><li>Start allopurinol after the acute attack has resolved.<ul><li>In circumstances where attacks are so frequent that this is not possible, the initiation of allopurinol can be considered before inflammation has completely settled.</li></ul></li><li>Start allopurinol at a low dose of 50-100 mg once a day (preferably taken with food), increased by 100 mg increments approximately every 4 weeks until the serum uric acid (SUA) level is below 300 micromol/L. <ul><li>For people with renal impairment starting dose and titration guidance may differ. See <a class=\"topic-reference internal-reference\" href=\"/topics/gout/prescribing-information/allopurinol/#managing-renal-impairment\">Managing renal impairment</a>.</li><li>The maximum dose of allopurinol for gout prophylaxis is 900mg daily in divided doses (lower in renal impairment).<ul><li>Allopurinol is usually given once a day. However, doses of over 300 mg per day should be taken in divided doses to help minimize any gastrointestinal adverse effects.</li></ul></li><li>Use a reduced dose in elderly people and in those with hepatic impairment:<ul><li>Prescribe an allopurinol starting dose of 50 mg once a day (allopurinol 50 mg tablets are not available, so when providing a 50 mg dose check that the 100 mg tablets are scored).</li></ul></li></ul></li><li>When starting or up-titrating allopurinol, flare prophylaxis using <a class=\"topic-reference internal-reference\" href=\"/topics/gout/prescribing-information/colchicine/\">colchicine</a> or an NSAID is recommended - see <a class=\"topic-reference internal-reference\" href=\"/topics/gout/management/preventing-gout/#drug-treatment\">Gout prevention</a> section.</li><li>If a gout flare occurs during treatment with allopurinol:<ul><li>Advise that allopurinol should <em>not </em>be discontinued.</li><li>Manage the flare as appropriate for the person.</li><li>Reassure the person that continuous treatment with allopurinol will decrease the frequency and intensity of further gout flares.</li></ul></li><li>Screening for HLA-B*5801 should be considered before starting treatment with allopurinol in patient subgroups where the prevalence of this allele is known to be high (for example people of Han Chinese, Thai and Korean origin).</li></ul><p>Information on prescribing allopurinol is based mainly on a guideline produced by expert representatives of the British Society for Rheumatology (BSR) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Hui, 2017</a>] and the Manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">ABPI, 2018a</a>].</p><!-- end field e7ec73e6-3ab2-4503-a0e8-283e555a1802 --><!-- end item 71b1f4b2-30fa-4773-90d1-a8dbf2e752a2 -->","subChapters":[]},{"id":"d709cc45-d80a-5252-bc25-0fa7afbdb84a","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field aacd1d55-0121-4421-93fd-2e70f2e4adf2 --><h3>How should I manage the adverse effects of allopurinol?</h3><!-- end field aacd1d55-0121-4421-93fd-2e70f2e4adf2 -->","summary":"","htmlStringContent":"<!-- begin item 4a655794-ac0e-453c-8718-4d20036e8ddf --><!-- begin field 980666e4-5b31-4a11-b27c-62738ef2dcc2 --><ul><li>There is a risk of precipitating acute attacks of gout after starting allopurinol.<ul><li>Advise people who experience acute attacks of gout after initiation of treatment with allopurinol, or during established treatment, to continue taking allopurinol.</li></ul></li><li>Rashes are common and can occur any time after starting allopurinol.<ul><li>Advise people who experience a rash to stop allopurinol immediately and seek prompt medical advice.</li><li>Rarely, exfoliative rashes such as Stevens Johnsons syndrome (SJS) or toxic epidermal necrolysis (TEN) can occur. A rash can be the first sign of a rare hypersensitivity reaction.</li><li>If SJS/TEN or a serious hypersensitivity reaction cannot be ruled out, allopurinol should not be re-introduced at any time. If the rash was mild and subsequently resolved, gradually reintroduce the allopurinol. If the rash recurs, immediately discontinue the allopurinol. </li></ul></li><li>Somnolence, vertigo, and ataxia have been reported with allopurinol use.<ul><li>Advise that when starting allopurinol, people should be cautious about driving or using machinery until they are reasonably certain that allopurinol does not adversely affect their performance.</li></ul></li><li>Since allopurinol and its metabolites are excreted by the kidney, impaired renal function may lead to retention of the drug and/or its metabolites, with consequent prolongation of plasma half-life.</li><li>People with chronic renal impairment who also take allopurinol may be at increased risk of hypersensitivity reactions. Treatment should be stopped immediately if a hypersensitivity reaction occurs.</li><li>Overall, adverse effects are rare but their incidence (particularly rashes) is higher in the presence of renal or hepatic impairment.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Hui, 2017</a>] </p><!-- end field 980666e4-5b31-4a11-b27c-62738ef2dcc2 --><!-- end item 4a655794-ac0e-453c-8718-4d20036e8ddf -->","subChapters":[]},{"id":"f4bd994d-8044-558b-9edf-925e13727301","slug":"managing-renal-impairment","fullItemName":"Managing renal impairment","depth":3,"htmlHeader":"<!-- begin field c132b04e-ecba-47ae-8e0b-119fa98d1ebf --><h3>How do I manage someone with renal impairment who requires allopurinol?</h3><!-- end field c132b04e-ecba-47ae-8e0b-119fa98d1ebf -->","summary":"","htmlStringContent":"<!-- begin item 26d4df31-1158-4384-b180-263328fc8b50 --><!-- begin field 486a76b9-1e33-4678-b9a9-5a2f583b4db3 --><ul><li>Since allopurinol and its metabolites are excreted by the kidney, impaired renal function may lead to retention of the drug and/or its metabolites, with consequent prolongation of plasma half-life.</li><li>The target serum uric acid level is the same as for people without renal impairment. However, when adjusting the dose, the maximum allopurinol dose increment should be 50mg.</li><li>In people with an estimated glomerular filtration rate (eGFR) less than 60 mL/min/1.73m<sup>2</sup> :<ul><li>Prescribe an allopurinol starting dose of 50 mg once a day (allopurinol 50 mg tablets are not available, so when providing a 50 mg dose check that the 100 mg tablets are scored).</li></ul></li><li>Increasing the initial dose interval may be required for people with severe renal impairment. Suggested safe starting doses are:<ul><li>eGFR 16-30 mL/min/1.73m<sup>2</sup> - 50mg every 2 days.</li><li>eGFR 5-15 mL/min/1.73m<sup>2</sup> - 50mg twice weekly.</li><li>eGFR less than mL/min/1.73m<sup>2</sup> - 50mg per week.</li></ul></li><li>Once allopurinol has been started, it is best to check urate levels and renal function every 2–4 weeks for the first 3 months.</li><li>People with chronic renal impairment who also take allopurinol may be at increased risk of hypersensitivity reactions and other adverse reactions - see adverse reactions.</li></ul><p>Information on prescribing allopurinol is based mainly on a guideline produced by expert representatives of the British Society for Rheumatology (BSR) [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">Hui, 2017</a>]  and the Manufacturer's Summary of Product Characteristics [<a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">ABPI Medicines Compendium, 2017a</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/gout/references/\">ABPI, 2018a</a>] . </p><p> </p><!-- end field 486a76b9-1e33-4678-b9a9-5a2f583b4db3 --><!-- end item 26d4df31-1158-4384-b180-263328fc8b50 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}